Abstract:As recombinant tissue plasminogen activator is the only drug approved for the clinical treatment of acute ischemic stroke, there is an urgent unmet need for novel stroke treatments. Endogenous defense mechanisms against stroke may hold the key to new therapies for stroke. A large number of studies suggest that nicotinamide phosphoribosyl-transferase (NAMPT is an attractive candidate to improve post-stroke recovery. NAMPT is a multifunctional protein and plays important roles in immunity, metabolism, aging, inflammation, and stress responses. NAMPT exists in both the intracellular and extracellular space. As a rate-limiting enzyme, the intracellular form (iNAMPT catalyzes the first step in the biosynthesis of nicotinamide adenine dinucleotide (NAD from nicotinamide. iNAMPT closely regulates energy metabolism, enhancing the proliferation of endothelial cells, inhibiting apoptosis, regulating vascular tone, and stimulating autophagy in disease conditions such as stroke. Extracellular NAMPT (eNAMPT is also known as visfatin (visceral fat-derived adipokine and has pleotropic effects. It is widely believed that the diverse biological functions of eNAMPT are attributed to its NAMPT enzymatic activity. However, the effects of eNAMPT on ischemic injury are still controversial. Some authors have argued that eNAMPT exacerbates ischemic neuronal injury non-enzymatically by triggering the release of TNF-α from glial cells. In addition, NAMPT also participates in several pathophysiological processes such as hypertension, atherosclerosis, and ischemic heart disease. Thus, it remains unclear under what conditions NAMPT is beneficial or destructive. Recent work using in vitro and in vivo genetic/ pharmacologic manipulations, including our own studies, has greatly improved our understanding of NAMPT. This review focuses on the multifaceted and complex roles of NAMPT under both normal and ischemic conditions.

[Research progress on nicotinamide phosphoribosyl transferase involved in aging and age-related diseases].

Nicotinamide phosphoribosyltransferase may be involved in age-related brain diseases.

The Role of Nicotinamide Phosphoribosyltransferase in Cerebral Ischemia

Nicotinamide Phosphoribosyltransferase as a Key Molecule of the Aging/Senescence Process

Nicotinamide Effects on the Metabolism of Human Fibroblasts and Keratinocytes Assessed by Quantitative, Label-Free Fluorescence Imaging

Nicotinamide N-Methyltransferase (NNMT): A New Hope for Treating Aging and Age-Related Conditions

Drug Discovery Targeting Nicotinamide Phosphoribosyltransferase (NAMPT): Updated Progress and Perspectives

Research advances in the function and anti-aging effects of nicotinamide mononucleotide

Discovery of a Potent Nicotinamide Phosphoribosyltransferase Activator for Improving Aging-associated Dysfunctions

Targeting NAD Metabolism for the Therapy of Age-Related Neurodegenerative Diseases

The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update

From Rate-Limiting Enzyme to Therapeutic Target: The Promise of NAMPT in Neurodegenerative Diseases

[Research advances on the roles of nicotinamide phosphoribosyltransferase in inflammation].

Nicotinamide Phosphoribosyltransferase Inhibitor Ameliorates Mouse Aging-Induced Cognitive Impairment

Targeting Nicotinamide Phosphoribosyltransferase As a Potential Therapeutic Strategy to Restore Adult Neurogenesis

NMN Nicotinamide Mononucleotide Activates Intracellular Energy and Approaches the Prevention and Improvement of Aging

NAD+ Deficiency Is a Common Central Pathological Factor of a Number of Diseases and Aging: Mechanisms and Therapeutic Implications

Channeling Nicotinamide Phosphoribosyltransferase (NAMPT) to Address Life and Death

Nicotinamide phosphoribosyltransferase and its roles in cancer

Research Progress of Nampt/Visfatin/PBEF

Nicotinamide Phosphoribosyltransferase Inhibitors in Cancer Therapy:An Advance